VANOS Cream and Skin Barrier Function
Completed · Phase 4
Conditions studied: Atopic Dermatitis
In brief
The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.
Key facts
- Study ID
- NCT00819507
- Run by
- Oregon Health and Science University
- People needed
- 25
- Starts
- 2009-01-01
- Expected to finish
- 2010-06-21
- Last updated by the study team
- 2017-07-11
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of AD according to Hanifin-Rajka criteria (see Appendix B)
- Age 12 years or older
- Must have an Investigator's Global Assessment (IGA) Score of Moderate, Severe, or Very Severe (See Appendix C)
- Must have failed to achieve adequate disease despite adequate topical or systemic therapy
- Must be a candidate, according to the principal investigator and standard of care, for a super-potent topical steroid course. Subjects that are candidates for super-potent topical steroids are defined as subjects whose disease is not adequately controlled with medium-potency topical steroids or systemic therapy, including phototherapy.
You may not qualify if…
- Active skin infection
- Hypersensitivity to any ingredients in Vanos cream
- Previous use of super-potent topical steroids within 2 weeks of starting study (Class I steroid).
Where it is running
- Oregon Health & Science University Department of Dermatology — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.